Related Experiment Video
Updated: Jul 6, 2026

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
Immunotherapy at clinical diagnosis of insulin-dependent diabetes: an approach still worth considering
1Endocrinology Unit, Department of Medicine II, University of Rome La Sapienza, Rome, Italy.
Immunointervention at the time of clinical diagnosis of insulin-dependent diabetes has been adopted in many centers throughout the world, with the aim of inducing and maintaining clinical remission (for example, reduction of insulin replacement therapy with normalization of metabolic parameters). Several approaches have been considered, ranging from the use of different kinds of immunosuppression to the use of free oxygen radical scavengers. Although the period of latency before the onset of overt hyperglycemia should be regarded as the most favorable time for any sort of immunointervention, adjuvant treatment at diagnosis (in addition to intensive insulin therapy) may offer clinical advantages in the long term. Thus, maintenance of some residual beta-cell function as a result o f such an approach may improve metabolic control and help to prevent the insurgence of late diabetic complications.
Immunointervention at the time of clinical diagnosis of insulin-dependent diabetes has been adopted in many centers throughout the world, with the aim of inducing and maintaining clinical remission (for example, reduction of insulin replacement therapy with normalization of metabolic parameters). Several approaches have been considered, ranging from the use of different kinds of immunosuppression to the use of free oxygen radical scavengers. Although the period of latency before the onset of overt hyperglycemia should be regarded as the most favorable time for any sort of immunointervention, adjuvant treatment at diagnosis (in addition to intensive insulin therapy) may offer clinical advantages in the long term. Thus, maintenance of some residual beta-cell function as a result o f such an approach may improve metabolic control and help to prevent the insurgence of late diabetic complications.
Related Concept Videos
Type I Diabetes I: Introduction
Tumor Immunotherapy
Type I Diabetes II: Pathophysiology
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

